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Testicular cancer (TC) affects 1 in 500males and is themostcommon malignancy among young men in western Euro-pean populations; for example, in Denmark 1% of all men
now develop TC.1–4 More than 97% of testes cancers are germ
cell tumours.4 Although the aetiology of these malignancies is
unknown, there is accumulating evidence of an intrauterine
stage of TC development that may involve both environmental
and genetic factors acting on the primordial gonocyte.4
Although many tumour suppressor genes have been studied,
there is little evidence supporting a role for these factors in the
pathogenesis of TC.5 A number of epidemiological studies
suggest that hypospadias, cryptorchidism, testicular cancer,
and male infertility may share, in part, a common aetiology
and this has given rise to the term “testicular dysgenesis
syndrome”.4 TC is associated with poor spermatogenic
function and recent data indicate that this dysfunction is
associated with impaired infertility several years before
diagnosis.6 Spermatogenic dysfunction is more common than
can be explained by either local tumour or general cancer
effect, since patients with other malignant diseases have nor-
mal, or only slightly decreased, semen quality.7
Human Y chromosome loss and rearrangements have been
associated with specific types of cancer, such as bladder
cancer, male sex cord stromal tumours, lung cancer, and
oesophageal carcinoma,8–11 suggesting that both oncogenes
and tumour suppressor genes exist on this chromosome. A
number of Y chromosome genes, or gene families, appear to be
necessary for male germ cell development and
maintenance12 13 and are candidates for involvement in
oncogenesis of male specific cancers. Indeed, a cancer predis-
position locus has been assigned to this chromosome, the
gonadoblastoma locus (GBY).14 The location, function, and
expression profile of the testis specific protein Y gene (TSPY) in
germ cell tumours, prostate tumours, and normal tissue sug-
gest that it is an excellent candidate for the GBY gene.15 Also,
the loss and gain of Y chromosome material and differential
expression of some Y genes was reported in prostate
cancers,16–20 reinforcing a role for the Y chromosome in malig-
nancy and cancer progression.
Y chromosome lineages are highly geographically stratified
among human populations. The variation of the non-
recombining region of the Y chromosome (NRY) has been
successfully used to study human origins and population
histories,21 22 based on the assumption that Y chromosome
variation is selectively neutral. However, if selection occurs,
themajority of the Y chromosomewill be affected, and not just
single genes, given the absence of recombination. An
increased (or decreased) frequency of a particular Y lineage in
the affected population may unmask the presence of a
functional variant, in linkage with the neutral mutation
defining the haplogroup. In this context, the choice of the
control population is critical, since statistical differences in
haplogroup frequencies between the affected and control
populations may be caused by population related factors (for
example, population substructure) and not by an actual
association with the phenotype under study. Several associa-
tions have already been reported between Y chromosome lin-
eages and various phenotypes, such as protection against Y
chromosome transfer to the X chromosome leading to XX-Y+
maleness,23 high blood pressure,24 and alcoholism.25 Con-
versely, absence of correlation has been reported between Y
variation and some behavioural disorders, such as autism26
and personality traits related to alcohol dependence.25
Recently, an association between Y background and reduced
sperm counts has been reported in Japanese27 and Danish
populations.28 In Denmark, a specific class of Y chromosomes,
hg26+, is associated with reduced sperm counts (<20 ×
106/ml), although the underlying molecular cause of this
reduction remains undefined.
It is conceivable that Y encoded factors, involved in germ
cell maturation, are implicated in the progression of TC. The
purpose of this study was to analyse the effects of the Y chro-
mosome background in testicular tumour formation. To assess
Y chromosome differences, seven unique event polymorphism
(UEP) markers and six microsatellites were used to construct
Key points
• The incidence of testicular cancer has increased world
wide by a factor of 3-4 during the last decades. The
observations of both an apparent decrease in semen
quality in the general population and a reduced
spermatogenic function in males presenting with testicu-
lar cancer suggest that both disorders may share a com-
mon aetiology.
• Since the human Y chromosome encodes several genes
necessary for germ cell development and maintenance,
it is possible that Y encoded factors are also involved in
testicular cancer formation or development.
• To test this hypothesis, we have analysed a set of 13 Y
linked polymorphisms (seven biallelic and six microsat-
ellite markers) to defined Y chromosome haplotypes in a
group of 43 English patients presenting with testicular
cancer. Their haplotype profile was compared with a
selected population of 179 controls to determine if there
is an association between Y chromosome background
and a predisposition to this cancer.
• When using three different levels of marker resolution,
the results of the exact test of population differentiation
indicated no significant differences between the case
and control groups. Although our data do not show a
correlation between a particular Y chromosome lineage
and a higher predisposition to testicular tumour
formation, a direct role of Y chromosome genes or gene
families in tumour formation or progression cannot be
excluded.
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haplotypes from a sample of 43 patients presenting with tes-
ticular cancer. Their Y haplogroup profile was compared with
a matched control population of English origin.
MATERIALS AND METHODS
Patients and controls
A total of 43 cases of testicular cancer patients of white Eng-
lish origin were recruited for the study from the general Man-
chester area. Out of the 43 cases, 30 presented with classical
seminoma, three with malignant undifferentiated teratoma
plus seminoma, three with malignant undifferentiated ter-
atoma plus yolk sac elements, three with malignant interme-
diate teratoma, two with malignant intermediate teratoma
plus seminoma, one with malignant undifferentiated ter-
atoma, and one with combined germ cell tumour with malig-
nant teratoma plus seminoma. The control population
consisted of 179 apparently healthy, unaffected subjects taken
from a larger data set described in Weale et al.29 They were
sampled from three Midlands towns (Ashbourne, Southwell,
and Bourne), each separated from the other by at least 30
miles, and all had paternal grandparents who were born in
England.
Molecular analysis
To define Y chromosome lineages in these subjects, we
analysed seven of the biallelic unique event polymorphism
(UEPs) markers (SRY-1532, 92R7, YAP, M9, LLY22g, Tat, 12f2)
and six microsatellites (DYS19, DYS388, DYS390, DYS391,
DYS392, DYS393). The seven biallelic markers, which are
known to be polymorphic in European populations and define
the main Y chromosomal haplogroups (fig 1), were analysed
as described in Rosser et al.36 The deep rooting markers
SRY1532,M9, 92R7, and YAP were typed in all samples and, in
some cases, the remaining markers were typed hierarchically,
for example, LLY22g and Tat only on those chromosomes M9
derived and 92R7 ancestral. The microsatellite typing was per-
formed as described in Thomas et al.37
Statistical analysis
To test for significant population differentiation between tes-
ticular cancer patients and the control population, we
performed the exact test of population differentiation,30 using
the ARLEQUIN package version 2.0.38 This test assays signifi-
cant departures from the null hypothesis of random distribu-
tion of alleles (or haplotypes) among population pairs. A
Markov chain of 10 000 steps was used and the significance
level of the test was set at 5%. Genetic diversity and its stand-
ard error were estimated using the unbiased formulae
described by Nei.39
RESULTS AND DISCUSSION
The UEP markers defined four different Y chromosome
lineages, or haplogroups (Hgs), in the testicular cancer
sample. Frequency distribution of Y chromosome lineages in
Figure 1 Schematic representation of the phylogenetic relationships among the Y chromosomal haplogroups. The markers that defined each
mutational step are reported and arrow orientation defines the ancestral and derivative state of each marker. Filled circles indicate haplogroups
not detected in either the control or the testicular cancer population.
Table 1 Y chromosome haplogroup (hg) distribution in testicular cancer patients
and in the relevant English control population
Population N Hg 1 Hg 2 Hg 3 Hg 9 Hg 21 Hg 26
Testicular cancer 43 32 8 2 – – 1
(%) 74.4 18.6 4.7 – – 2.3
English population 179 117 39 8 8 7 –
(%) 65.4 21.8 4.4 4.4 3.9 –
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Table 2 UEP and microsatellite combined haplotype frequencies in the testicular
cancer (TC) and English control population
Haplogroup Microsatellite haplotype* TC (n=43) %
Control
(c=179) %
Hg 1 12 12 23 11 13 13 – – 2 1.12
12 12 24 10 13 13 – – 1 0.56
12 12 24 11 13 13 – – 1 0.56
13 12 23 10 13 13 – – 1 0.56
13 12 24 10 13 14 – – 1 0.56
13 12 24 11 13 13 – – 2 1.12
14 10 23 11 13 13 – – 1 0.56
14 11 23 10 12 13 – – 1 0.56
14 12 23 10 13 13 – – 7 3.91
14 12 23 10 14 13 1 2.33 – –
14 12 23 11 13 13 5 11.63 19 10.61
14 12 23 11 13 14 – – 1 0.56
14 12 24 10 12 13 1 2.33 – –
14 12 24 10 13 12 – – 1 0.56
14 12 24 10 13 13 3 6.98 20 11.17
14 12 24 10 13 14 2 4.65 1 0.56
14 12 24 10 14 13 – – 2 1.12
14 12 24 11 12 13 – – 1 0.56
14 12 24 11 13 12 1 2.33 1 0.56
14 12 24 11 13 13 10 23.26 23 12.85
14 12 24 11 13 14 – – 1 0.56
14 12 24 12 13 13 – – 2 1.12
14 12 24 13 13 13 – – 1 0.56
14 12 25 10 13 13 – – 3 1.68
14 12 25 11 13 12 – – 4 2.23
14 12 25 11 13 13 1 2.33 5 2.79
14 12 25 11 14 13 2 4.65 – –
14 13 23 11 13 13 – – 1 0.56
14 13 24 10 12 13 – – 1 0.56
15 12 23 10 13 13 1 2.33 2 1.12
15 12 23 11 13 13 – – 4 2.23
15 12 24 10 13 13 2 4.65 2 1.12
15 12 24 11 13 13 1 2.33 3 1.68
15 12 24 11 13 14 – – 1 0.56
15 12 24 11 15 13 – – 1 0.56
16 12 24 10 13 13 1 2.33 – –
16 12 25 11 14 14 1 2.33 – –
Hg 2 14 12 21 10 11 14 – – 1 0.56
14 12 22 10 11 13 – – 1 0.56
14 14 22 10 11 13 2 4.65 8 4.47
14 14 22 10 11 14 2 4.65 – –
14 14 22 11 11 12 – – 1 0.56
14 14 23 10 11 13 1 2.33 4 2.23
14 14 23 11 11 13 1 2.33 – –
14 16 22 09 11 14 – – 1 0.56
14 16 22 10 11 13 – – 1 0.56
15 12 21 10 11 14 – – 1 0.56
15 12 22 11 11 14 – – 1 0.56
15 13 22 10 11 14 – – 1 0.56
15 13 23 10 12 14 – – 3 1.68
15 13 23 10 12 15 – – 3 1.68
15 13 23 11 12 14 – – 1 0.56
15 13 24 10 12 15 – – 1 0.56
15 14 22 10 11 12 1 2.33 – –
15 14 22 10 11 13 1 2.33 3 1.68
15 14 22 11 11 13 – – 1 0.56
15 15 23 10 11 13 – – 1 0.56
16 13 23 10 12 13 – – 1 0.56
16 13 23 10 13 13 – – 1 0.56
16 13 24 10 12 14 – – 1 0.56
16 14 22 10 11 13 – – 2 1.12
17 13 23 11 12 14 – – 1 0.56
Hg 3 15 12 23 10 11 12 – – 1 0.56
15 12 25 11 11 13 1 2.33 – –
16 12 24 10 11 13 – – 1 0.56
16 12 25 10 11 13 1 2.33 2 1.12
16 12 25 10 11 14 – – 1 0.56
16 12 25 11 11 13 – – 2 1.12
17 12 25 10 11 13 – – 1 0.56
contd
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TC patients is indicated in table 1, together with that of the
English control population. Because the control group
comprised three samples from separate towns in central Eng-
land, and because a previous study on these samples has
found no significant differences in Y chromosome frequencies
among these towns,29 the chances of geographical substruc-
turing in the control group is minimised. The most frequent
Hgs in the TC patients are Hg 1 (74%) and Hg 2 (19%) and, at
lower frequencies, Hg 3 (5%) and Hg 26 (2%). The haplogroup
profile observed in the TC sample is consistent with that
observed in the control English population, where Hgs 1 and 2
are the most representative lineages. To compare haplogroup
distribution between the affected and control populations, an
exact test of population differentiation was performed.30 The
results of this test, based on frequency distribution, indicate
no significant differences in haplogroup distribution between
the TC and control groups (p=0.23 ± 0.008). However, the
failure to find any statistical association between a Y chromo-
some haplogroup and incidence of testicular cancer may be
because of an insufficient definition of the Y chromosome
haplogroups, solely based on UEP markers. Indeed, some of
these lineages are paraphyletic groups that show a high within
haplogroup diversity. Thus, it is plausible that a particular
sublineage within a haplogroupmay show an association with
a Y chromosome phenotype but not the whole lineage. There-
fore,we sought to refine further the Y chromosome lineages in
the testicular cancer subjects, by analysing a set of six micro-
satellite markers.
Among the 43 subjects studied, 23 distinct six locus haplo-
types were observed (table 2). Genetic diversity, which
estimates the probability that two randomly chosen haplo-
types are different in the sample, was high (h=0.93 ± 0.027),
and comparable to that found in the control sample (h=0.95
± 0.008). This argues against a strong association between tes-
ticular cancer and a recent causative mutation, as this would
result in a lower diversity in the TC sample. A comparison of
microsatellite haplotype distribution between the TC sample
and the matched control population also failed to show any
statistical difference between the two groups (p=0.57 ±
0.027). Because there might be an intermediate level of reso-
lution between the full microsatellite haplotype and the UEP
based haplogroup where a difference between cases and con-
trols could reveal itself, we also split the two main
haplogroups (Hg 1 and Hg 2) into two subcategories according
to whether or not the microsatellite haplotype belonged to the
modal cluster (defined as haplotypes belonging to or one step
removed from the modal haplotype in each haplogroup; note
both cases and controls had the same the modal haplotype for
Hg 1 and Hg 2). However, we again failed to find a significant
difference at this level of resolution between cases and
controls (p=0.16 ± 0.008).
Although we did not detect an association between Y chro-
mosome background and testicular tumour formation, this
does not exclude a Y chromosome contribution to the
aetiopathogenesis of this cancer. For example, Hg 1 has the
highest observed haplogroup association with testicular
cancer, with an estimated odds ratio of 1.54 (95% CI
0.74-3.22). Because of the wide confidence intervals, it is pos-
sible that a high association with a particular Y chromosome
type exists (for example, the real odds ratio with Hg 1 could be
as high as 3.22) but remained hidden in our study. An
alternative approach to uncover an association between the Y
chromosome and TC may be to examine directly Y chromo-
some gene copy number in populations with distinct ethnic
backgrounds and to compare their profiles with relevant sam-
ples of patients presenting with testicular dysfunction. In this
context, the Y located TSPY gene family may play a role in
oncogenesis because of its expression profile (male germ cells
and neoplasia of the testis), and its homology to the SET
oncogene, a cyclin B binding protein.31 TSPY is polymorphic in
copy number (20-40 copies) and is arranged in a tandemly
organised cluster,32 which exhibits interperson polymorphism
in gene copy number33 that may be associated with phenotype
variation. In addition, the DAZ and RBMY genes are also
present in multiple copies along the Y chromosome and have
a germ cell specific expression profile.34 Indeed, the autosomal
homologue of DAZ, DAZL1, is expressed in testicular germ cell
tumours.35
In conclusion, although our data do not show an effect of
the Y chromosome background in testicular cancer in a cohort
of English patients, it is necessary to study other populations
where the incidence of TC is rising dramatically and where a Y
chromosome haplogroup has been found to be associated with
reduced testicular function, such as in Denmark.28
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